Cheng Yanping, Ferrone Marco, Wang Qing, Perkins Laura E L, McGregor Jennifer, Redfors Björn, Zhou Zhipeng, Rapoza Richard, Conditt Gerard B, Finn Aloke, Virmani Renu, Kaluza Grzegorz L, Granada Juan F
CRF Skirball Center for Innovation, Orangeburg, New York.
Abbott Vascular, Santa Clara, California.
JACC Basic Transl Sci. 2020 Jun 3;5(6):619-629. doi: 10.1016/j.jacbts.2020.04.005. eCollection 2020 Jun.
The integration of the Absorb bioresorbable vascular scaffold (BVS) into the arterial wall has never been tested in an in vivo model of atherosclerosis. This study aimed to compare the long-term (up to 4 years) vascular healing responses of BVS to an everolimus-eluting metallic stent in the familial hypercholesterolemic swine model of atherosclerosis. The multimodality imaging and histology approaches indicate that the resorption and vascular integration profile of BVS is not affected by the presence of atherosclerosis. BVS demonstrated comparable long-term vascular healing and anti-restenotic efficacy to everolimus-eluting metallic stent but resulted in lower late lumen loss at 4 years.
在动脉粥样硬化的体内模型中,从未对Absorb生物可吸收血管支架(BVS)与动脉壁的整合情况进行过测试。本研究旨在比较在家族性高胆固醇血症猪动脉粥样硬化模型中,BVS与依维莫司洗脱金属支架的长期(长达4年)血管愈合反应。多模态成像和组织学方法表明,BVS的吸收和血管整合情况不受动脉粥样硬化存在的影响。BVS显示出与依维莫司洗脱金属支架相当的长期血管愈合和抗再狭窄疗效,但在4年时导致更低的晚期管腔丢失。